Biomedical Engineering Reference
In-Depth Information
192. Savelieva I, Camm J (2008) Antiarrhythmic drug therapy for atrial fibrillation: current anti-
arrhythemic drugs,
investigational
agents
and innovative
approaches. Europace
10:647-665
193. Goldstein RN, Christion C, Carlson L, Waldo AL (2004) AZD 7009: a new antiarrhythmic
drug with predominant effect on the atria effectively terminates and prevents reinduction of
atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol
15:1444-1450
194. Osterman PO, Westerberg CE (1975) Paroxysmal symptoms in multiple sclerosis. Brain
98:189-202
195. Clifford DB, Trotter JL (1984) Pain in multiple sclerosis. Arch Neurol 41:1270-1272
196. Sakurai M, Kanazawa I (1999) Positive symptoms in multiple sclerosis: their treatment with
sodium channel blockers, lidocaine and mexiletine. J Neurol Sci 162:162-168
197. Bechtold DA, Miller SJ, Dawson AC, Sun Y, Kapoor R, Berry D, Smith KJ (2006) Axonal
protection achieved in a model of multiple sclerosis using lamotrigine. J Neurol
253:1542-1551
198. Kapoor R (2006) Neuroprotection in multiple sclerosis: therapeutic strategies and clinical
trial design. Curr Opin Neurol 19:255-259
199. Comi G, Filippi M (2005) Clinical trials in multiple sclerosis: methodological issue. Curr
Opin Neurol 9:220-229
200. Pieri M, Carunchio I, Curcio L, Mercuri NB, Zona C (2009) Increased persistent sodium
current determines cortical hyperexcitability in a genetic model of amyotrophic lateral
sclerosis. Exp Neurol 215:368-379
201. Song JH, Huang CS, Nagata K, Yeh JZ, Narahashi T (1997) Differential action of riluzole on
tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther
282:707-714
202. Miller RG, Mitchell JD, Lyon M, Moore DH (2007) Riluzole for amyotrophic lateral sclerosis
(ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. doi:10.1002/14651858.
CD001447.pub2 DOI:dx.doi.org
203. Barn´oud P, Mazadier M, Miquet J-M, Parmentier S, Dub´dat P, Doble A, Boireau A (1996)
Neuroprotective effects of riluzole on a model of Parkinson's disease in the rat. Neuroscience
74:971-983
204. Jankovic J (2008) Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg
Psychiatry 79:368-376
205. Stocchi F, Vacca L, Grassini P, De Pandis MF, Battaglia G, Cattaneo C, Fardello RG (2006)
Symptom relief in Parkinson disease by safinamide - biochemical and clinical evidence of
efficacy beyond MAO-B inhibition. Neurology 67:S24-S29
206. Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli R, Curatolo L, Salvati P, Fardello RG
(2006) Safinamide from molecular targets to a new antiparkinson drug. Neurology 67:
S18-S23
207. Parkinson Study Group (2001) A randomized, controlled trial of remacemide for motor
fluctuations in Parkinson's disease. Neurology 56:455-462
208. Walker FO (2007) Huntington's disease. Lancet 369:218-228
209. Kieburtz K, Feigin A, McDermott M, Como P, Abwender D, Zimmerman C, Hickey C, Orme
C, Claude K, Sotack J, Greenamyre JT, Dunn C, Shoulson I (1996) A controlled trial of
remacemide hydrochloride in Huntington's disease. Mov Disord 11:273-277
210. Wong H-K, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H, Kurosawa M, De Strooper
B, Saftig P, Nukina N (2005)
b
Subunits of voltage-gated sodium channels are novel
substrates of
b
-site amyloid precursor protein-cleaving enzyme (BACE1) and
g
-secretase. J
Biol Chem 280:23009-23017
211. Post RM (2004) Differing psychotropic profiles of the anticonvulsants in bipolar and other
psychiatric disorders. Clin Neurosci Res 4:9-30
212. Boylan LS, Devinsky O, Barry JJ, Ketter TA (2002) Psychiatric uses of antiepileptic
treatments. Epilepsy Behav 3:S54-S59
